Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

December 3, 2025 0

Harmony Biosciences Epilepsy News and the Treatment of Dravet Syndrome Harmony Biosciences Holdings, Inc. (HRMY), announced that it will highlight new open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy Society (AES) Annual Meeting being held December 5 – December 9, 2025, in Atlanta, GA. The …

Eli Lilly Lowers the Price of Zepbound® (tirzepatide) Single-Dose Vials

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate...

Regeneron: DB-OTO Results in Sustained Improvement in Hearing and Speech...

VectorY Therapeutics and Shape Therapeutics, both private firms Announce Option...

Helping Your Pets to be Healthy and Live Longer

Praxis Precision Medicines Radiant Study with Vormatrigine

ARS Pharmaceuticals Announces FDA Approval of neffy® for Type I...

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its...

Iterum Therapeutics Receives US FDA Approval of ORLYNVAH™ for the...

The United States FDA Approved Astellas’ product VYLOY in Combination...

U.S. FDA Approves AbbVie’s VYALEV™ for Adults Living with Advanced...

Novo Nordisk Launches New Initiative To Prevent Childhood Obesity In...

The FDA Approved IntraBio Product AQNEURSA As the only treatment...

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet...

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients...

SCG Cell Therapy: FDA Approved IND Application of Product SCG142...

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612...

AstraZeneca: The U.S. FDA Approved IMFINZI in Combination with Carboplatin...

Regeneron: Improved Hearing to Normal Levels in a Child with...

Impacting News

The U.S. FDA Approved Vanda Pharmaceuticals Product NEREUS™ for Prevention of Vomiting Induced by Motion

January 2, 2026 0

Vanda Pharmaceuticals During December 2025, Vanda Pharmaceuticals Inc. (VNDA) announced that the U.S. Food and Drug …

Happy New Year 2026

December 30, 2025 0

Happy New Year 2026 Following the celebrations of Faiths, we wish you all that you believe …

Alnylam Pharmaceuticals Announces Partial Repurchase of 1% Convertible Senior Notes Due 2027

December 12, 2025 0

Alnylam Pharmaceuticals Yesterday, December 11, 2025, Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has entered into …

Praxis Precision Medicines Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen In Early Onset SCN2A Developmental and Epileptic Encephalopathy

December 10, 2025 0

Praxis Precision Medicines Praxis Precision Medicines (PRAX) - a clinical-stage biopharmaceutical company translating genetic insights into the …

Ionis receives U.S. FDA Breakthrough Therapy Designation for Zilganersen for Alexander Disease

December 4, 2025 0

Ionis Pharmaceuticals On December 2, 2025 - Ionis Pharmaceuticals (IONS) announced that the FDA has granted …

Roche: FDA Clearance with CLIA Waiver and CE Mark for its First Point-of-Care Test for Diagnosing Bordetella Infections, Including Whooping Cough

December 3, 2025 0

Roche in the NEWS Basel, December 2, 2025 - Roche (RHHBY) announced that its first point-of-care …

Trick or Trade

Milestone Receives FDA Approval of CARDAMYST™ as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia

December 16, 2025 0

Milestone in the NEWS MONTREAL and CHARLOTTE, Milestone® (MIST) announced that the U.S. FDA approved its first …

About Time to Remember, and Today and Many Days Before

December 9, 2025 0

About Time to Remember A few days ago, Governor Ron DeSantis eliminated property taxes for property …

A Question And An Answer

December 2, 2025 0

Question & Answer About Cogen Biosciences Question From Mel Nashef Q: On November 24, 2025, …

Cogent Biosciences Has Excellent NEWS

November 24, 2025 0

Cogent Biosciences Excellent NEWS Cogent Biosciences (COGT) develops precision therapies for patients with genetically defined diseases. …

In Data Presented at the European Association for the Study of Diabetes and NEUROdiabetis Meetings, Lexicon Pharmaceuticals Product Pilavapadin Provided Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain.

September 18, 2025 0

Lexicon Pharmaceuticals in the NEWS Yesterday, September 17, 2025, Lexicon Pharmaceuticals (LXRX) announced the presentation of …

The FDA is Taking Concrete Steps to Reduce Opioid Misuse, Addiction and Overdose Strengthening Guidance on Their Appropriate Use

September 11, 2025 0

Xenon Pharmaceuticals A Company Treating Chronic Pain Xenon Pharmaceuticals (XENE) - a neuroscience-focused biopharmaceutical company dedicated …

Today’s Highlights

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

December 18, 2025 0

BioNTech in the NEWS MAINZ, Germany, December 18, 2025 – BioNTech SE (BNTX) announced the closing of …

Novo Nordisk Files for FDA Approval of CagriSema, the First Once-Weekly Combination of GLP‑1 and Amylin Analogues for Weight Management

December 18, 2025 0

Novo Nordisk PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Dec. 18, 2025 /PRNewswire/ -- Today, Novo Nordisk (NVO) announced the submission of a …

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

December 15, 2025 0

Immunome Inc Immunome, Inc. (IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer …

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial Setmelanotide Demonstrating Positive Efficacy Signal in Prader-Willi Syndrome

December 11, 2025 0

Rhythm Pharmaceuticals Today, Rhythm Pharmaceuticals, Inc. (RYTM), announced positive preliminary results from its exploratory Phase 2 trial …

Merck to Acquire Cidara Therapeutics Inc Diversifying Its Portfolio To Include Late-Phase Antiviral Agent

November 14, 2025 0

Merck to Acquire Cidara Therapeutics Merck (NYSE: MRK), known as MSD outside of the United States …

Cidara Therapeutics Provides Corporate Update and Reports Q3 2025 Results

November 7, 2025 0

Cidara Therapeutics Q3 Financial Results SAN DIEGO, November 06, 2025, Cidara Therapeutics, Inc. (CDTX) reported financial …

Latest Articlesddd

The U.S. FDA Approved Vanda Pharmaceuticals Product NEREUS™ for Prevention of Vomiting Induced by Motion

January 2, 2026 0

Vanda Pharmaceuticals During December 2025, Vanda Pharmaceuticals Inc. (VNDA) announced that the U.S. Food and Drug …

Happy New Year 2026

December 30, 2025 0

Happy New Year 2026 Following the celebrations of Faiths, we wish you all that you believe …

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

December 18, 2025 0

BioNTech in the NEWS MAINZ, Germany, December 18, 2025 – BioNTech SE (BNTX) announced the closing of …

Novo Nordisk Files for FDA Approval of CagriSema, the First Once-Weekly Combination of GLP‑1 and Amylin Analogues for Weight Management

December 18, 2025 0

Novo Nordisk PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Dec. 18, 2025 /PRNewswire/ -- Today, Novo Nordisk (NVO) announced the submission of a …

Milestone Receives FDA Approval of CARDAMYST™ as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia

December 16, 2025 0

Milestone in the NEWS MONTREAL and CHARLOTTE, Milestone® (MIST) announced that the U.S. FDA approved its first …

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

December 15, 2025 0

Immunome Inc Immunome, Inc. (IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer …

Alnylam Pharmaceuticals Announces Partial Repurchase of 1% Convertible Senior Notes Due 2027

December 12, 2025 0

Alnylam Pharmaceuticals Yesterday, December 11, 2025, Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has entered into …

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial Setmelanotide Demonstrating Positive Efficacy Signal in Prader-Willi Syndrome

December 11, 2025 0

Rhythm Pharmaceuticals Today, Rhythm Pharmaceuticals, Inc. (RYTM), announced positive preliminary results from its exploratory Phase 2 trial …

Praxis Precision Medicines Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen In Early Onset SCN2A Developmental and Epileptic Encephalopathy

December 10, 2025 0

Praxis Precision Medicines Praxis Precision Medicines (PRAX) - a clinical-stage biopharmaceutical company translating genetic insights into the …

About Time to Remember, and Today and Many Days Before

December 9, 2025 0

About Time to Remember A few days ago, Governor Ron DeSantis eliminated property taxes for property …

Ionis receives U.S. FDA Breakthrough Therapy Designation for Zilganersen for Alexander Disease

December 4, 2025 0

Ionis Pharmaceuticals On December 2, 2025 - Ionis Pharmaceuticals (IONS) announced that the FDA has granted …

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

December 3, 2025 0

Harmony Biosciences Epilepsy News and the Treatment of Dravet Syndrome Harmony Biosciences Holdings, Inc. (HRMY), announced …

Roche: FDA Clearance with CLIA Waiver and CE Mark for its First Point-of-Care Test for Diagnosing Bordetella Infections, Including Whooping Cough

December 3, 2025 0

Roche in the NEWS Basel, December 2, 2025 - Roche (RHHBY) announced that its first point-of-care …

A Question And An Answer

December 2, 2025 0

Question & Answer About Cogen Biosciences Question From Mel Nashef Q: On November 24, 2025, …

Eli Lilly Lowers the Price of Zepbound® (tirzepatide) Single-Dose Vials

December 1, 2025 0

Lilly in the NEWS INDIANAPOLIS, December 1, 2025, Eli Lilly and Company (LLY) today announced Zepbound® …

Cogent Biosciences Has Excellent NEWS

November 24, 2025 0

Cogent Biosciences Excellent NEWS Cogent Biosciences (COGT) develops precision therapies for patients with genetically defined diseases. …

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs, Including Parkinson’s Disease

November 21, 2025 0

Aspen Neuroscience Aspen Neuroscience, Inc. – a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced the …